SQZ Biotech Named One of "Fierce 15" Biotech Companies of 2015

SQZ Biotech Named One of "Fierce 15" Biotech Companies of 2015
Transformative CellSqueeze Platform Recognized as Most Promising in Industry

Cambridge, MA – September 30, 2015 – SQZ Biotech today announced that it has been named by FierceBiotech as one of 2015's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. Based on science discovered by Massachusetts Institute of Technology (MIT) professors Drs. Klavs Jensen, Robert Langer, and Armon Sharei, the pioneering company has developed the CellSqueeze platform that enables a variety of materials to enter almost any cell type, including primary human derived cells, with unprecedented efficacy. The platform addresses one of the major barriers to cell engineering and has the potential to revolutionize future therapies.

SQZ co-founder and chief executive officer, Dr. Sharei expressed gratitude for the recognition and enthusiasm for the future impact of the company's groundbreaking science: "We are thrilled to be recognized alongside such a distinguished cadre of companies all seeking to make a meaningful impact in our respective fields of science," said Dr. Sharei. "Our momentum continues towards developing novel cell therapies using our foundational cell engineering platform and we anticipate an extremely exciting year ahead."

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech's thirteenth annual Fierce 15 selection. A complete list of "Fierce 15" companies can be found online at www.fiercebiotech.com/fierce15.

An internationally recognized daily report reaching a network of over 275,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

About SQZ Biotech

Cell therapies have much potential to address our most challenging diseases. However the difficulty of engineering patient cells in an effective, scalable manner has limited impact. SQZ Biotech seeks to address this fundamental problem by developing its CellSqueeze platform for use in multiple clinical indications. SQZ's technology has overcome longstanding barriers in the field by facilitating more effective access to the intracellular space. Through internal research programs and external partnerships, SQZ is leading a revolution in scientists' approach to disease research and clinical therapies, developing novel methods to engineer cell function and harnessing the power of a patient's own cells to combat disease more effectively across a broad range of indications.

About FierceBiotech
FierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signup is free at www.fiercebiotech.com/signup.


###


CONTACTS:
Rebecca Friend
FierceBiotech
202-824-5050
[email protected]
Emily Mendell
SQZ Biotech
781-522-6732
[email protected]

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.